Pulmonx Corporation (LUNG)
After hours:
| Previous close | 7.84 |
| Open | 7.99 |
| Bid | 7.71 x 100 |
| Ask | 7.78 x 100 |
| Day's range | 7.74 - 8.07 |
| 52-week range | 5.67 - 14.84 |
| Volume | |
| Avg. volume | 396,749 |
| Market cap | 300.822M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.83 |
GlobeNewswirePulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “In
ZacksHow Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on Ma
